Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.

Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2008 in Chicago, Illinois.

Updated results and a comparative safety and response analysis in older patients (>/= 60 years old) and younger patients (< 60 years old) from the company's Phase 1 clinical trial of voreloxin in relapsed or refractory acute leukemia patients will be presented at the 13th Congress of the European Hematology Association (EHA) being held June 12 - 15, 2008 in Copenhagen, Denmark. The presentation will also include preliminary data from the company's Phase 1b trial of voreloxin combined with cytarabine in relapsed/refractory acute myeloid leukemia (AML) patients. In addition, data from the company's ongoing Phase 1 clinical trial of SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma will be presented at EHA.

44th ASCO Annual Meeting

o A PHASE 2 TRIAL OF SNS-595 IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL

OVARIAN CANCER

Abstract #5582

General poster session Gynecologic Cancer: Ovarian Cancer

Saturday, May 31, 2008, 8:00 a.m. - 12:00 p.m. CST, S Hall A1

13th Congress of the European Hematology Association

o SAFETY AND EFFICACY EXPERIENCE OF SNS-595 IN RELAPSED/REFRACTORY ACUTE

LEUKEMIA PATIENTS >/= 60 YEARS OLD COMPARED TO < 60 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February ... ... to correct pelvic organ prolapse with the latest techniques and the most minimally ... risk for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR ... AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is ... 5000 perioperative nurses in attendance to study the latest evidence-based recommendations and ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ... indicated by the table. By manipulating each pixel, LUT's can change each color range ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):